Prof. Wu and Prof. Mo has topped the New England Journal of Medicine for the second time by virtue of their research AURA3 to cure T790 mutation of lung cancer after OHI Tartini (AZD9291) treating Gefitnib’s drug- resistance ! The treatment to lung cancer makes great progress!

In 2009, Prof. Wu and Prof. Mo ‘s research IPASS about Gefitnib’s treatment of non small-cell lung cancer published on the New England Journal, which started a new stage for the treatment of the cell of lung cancer, and also accelerated the research of lung cancer.

On the12th December, 2016, Prof. Wu and Prof. Mo topped the New England Journal of Medicine for the second time by virtue of their research AURA3 to cure T790 mutation of lung cancer after OHI Tartini (AZD9291) treating Gefitnib’s drug- resistance ! The treatment to lung cancer makes great progress!

AUAR-3 research recently published on the the New England Journal of Medicine

IPASS research published on the the New England Journal of Medicine in 2009

Chinese scholars’ research on lung cancer has been increasingly honed, approaching the world’s leading position! Chinese scholars have become an important part of the world in the field of lung cancer research! Congratulations to Prof. Wu Yilong! Congratulations to Prof. Mo Shujin! Pictures and text from physician tumor information exchange)